Beam Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Beam Therapeutics generated cash of -$149,195,000, which is less than the previous year. Cash used in financing activities reached the amount of $276,448,000 last year. Net change in cash is therefore $199,093,000.
Cash Flow
| 2017 | -2.70M | -346K | 4.98M |
|---|---|---|---|
| 2018 | -20.29M | -13.42M | 179.72M |
| 2019 | -72.00M | -66.65M | 41.27M |
| 2020 | -95.74M | -100.12M | 322.32M |
| 2021 | -66.26M | -294.14M | 756.14M |
| 2022 | 22.52M | -461.33M | 111.59M |
| 2023 | -149.19M | 71.84M | 276.44M |
BEAM Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 245.52M | 572.74M | 177.01M | 50.55M | 147.93M | 1.93M | 0 |
Operating activities | |||||||
Net income | -132.52M | -289.08M | -370.63M | -194.59M | -78.32M | -116.73M | -8.00M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 20.01M | 14.14M | 7.45M | 4.73M | 3.50M | 650K | 11K |
Stock-based compensation expense | 98.64M | 84.32M | 43.57M | 15.38M | 7.02M | 0 | 198K |
| Deferred income tax benefit | 98.64M | 84.32M | 43.57M | 15.38M | 7.02M | 0 | 198K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 300M | -300M | 0 | 0 | 0 | 0 |
Inventories | 0 | -300M | 300M | 0 | 0 | 0 | 0 |
Accounts payable | -7.57M | 2.37M | 818K | 60K | 4.09M | 2.43M | 726K |
Cash generated by operating activities | -149.19M | 22.52M | -66.26M | -95.74M | -72.00M | -20.29M | -2.70M |
Investing activities | |||||||
Purchases Of Investments | -984.33M | -1.61B | -777.22M | -282.36M | -130.21M | -300K | 0 |
Investments In Property Plant And Equipment | -33.73M | -48.95M | -46.81M | -16.35M | -12.51M | -13.12M | -346K |
Acquisitions Net | 0 | 412.38M | 620K | 83.76M | 54.14M | 0 | 0 |
Cash generated by investing activities | 71.84M | -461.33M | -294.14M | -100.12M | -66.65M | -13.42M | -346K |
Financing activities | |||||||
Common Stock Issued | 270.16M | 108.25M | 757.44M | 320.62M | 37.90M | 179.72M | 4.98M |
Payments for dividends | 0 | 0 | 0 | 0 | -12.71M | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -25.18M | 0 | 0 |
Repayments of term debt | -2.25M | -2.28M | -2.11M | -1.69M | 5.71M | 0 | 0 |
Cash used in financing activities | 276.44M | 111.59M | 756.14M | 322.32M | 41.27M | 179.72M | 4.98M |
Net Change In Cash | 199.09M | -327.21M | 395.72M | 126.45M | -97.38M | 146.00M | 1.93M |
Cash at end of period | 444.61M | 245.52M | 572.74M | 177.01M | 50.55M | 147.93M | 1.93M |
| Data source | Data source | Data source | Data source | Data source |